Next Article in Journal
When the Patient Is Also a Carer
Previous Article in Journal
Molecular Progression in Unusual Recurrent Non-Pediatric Intracranial Clear Cell Meningioma
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Carcinoma Ex Pleomorphic Adenoma: Case Report and Options for Systemic Therapy

1
Department of Medical Oncology, BC Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada
2
BC Cancer Research Centre, Vancouver, BC, Canada
3
Department of Diagnostic Imaging, BC Cancer Agency, Vancouver, BC, Canada
4
Department of Pathology and Laboratory Medicine, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada
5
Department of Pathology and Laboratory Medicine, BC Cancer Agency, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(3), 251-254; https://doi.org/10.3747/co.24.3588
Submission received: 4 March 2017 / Revised: 5 April 2017 / Accepted: 8 May 2017 / Published: 1 June 2017

Abstract

The most common benign salivary tumour is a pleomorphic adenoma. Transformation to malignancy, carcinoma ex pleomorphic adenoma (CXPA), occurs in 6% of cases. Management focuses on surgical resection and radiotherapy; however, rare cases require systemic management. We present the case of a 60-year-old woman with a CXPA of the left parotid gland who required systemic therapy for locally recurrent disease. Treatment options were guided by the literature concerning malignant salivary gland tumour and by whole-genome and transcriptome sequencing of the tumour. The patient received multiple systemic agents during the course of her disease, with cyclophosphamide–doxorubicin–cisplatin providing the best control (partial response). Genomeand transcriptome-directed therapy, including sorafenib and vismodegib, were utilized with limited clinical benefit. Malignant transformation in CXPA is a complex process, and therapy directed at a single tumour pathway might not be sufficient to control disease.
Keywords: carcinoma ex pleomorphic adenoma; chemotherapy; cyclophosphamide; doxorubicin; cisplatin carcinoma ex pleomorphic adenoma; chemotherapy; cyclophosphamide; doxorubicin; cisplatin

Share and Cite

MDPI and ACS Style

Chooback, N.; Shen, Y.; Jones, M.; Kasaian, K.; Martin, M.; Ng, T.; Thomson, T.; Marra, M.; Laskin, J.; Ho, C. Carcinoma Ex Pleomorphic Adenoma: Case Report and Options for Systemic Therapy. Curr. Oncol. 2017, 24, 251-254. https://doi.org/10.3747/co.24.3588

AMA Style

Chooback N, Shen Y, Jones M, Kasaian K, Martin M, Ng T, Thomson T, Marra M, Laskin J, Ho C. Carcinoma Ex Pleomorphic Adenoma: Case Report and Options for Systemic Therapy. Current Oncology. 2017; 24(3):251-254. https://doi.org/10.3747/co.24.3588

Chicago/Turabian Style

Chooback, N., Y. Shen, M. Jones, K. Kasaian, M. Martin, T. Ng, T. Thomson, M. Marra, J. Laskin, and Cheryl Ho. 2017. "Carcinoma Ex Pleomorphic Adenoma: Case Report and Options for Systemic Therapy" Current Oncology 24, no. 3: 251-254. https://doi.org/10.3747/co.24.3588

APA Style

Chooback, N., Shen, Y., Jones, M., Kasaian, K., Martin, M., Ng, T., Thomson, T., Marra, M., Laskin, J., & Ho, C. (2017). Carcinoma Ex Pleomorphic Adenoma: Case Report and Options for Systemic Therapy. Current Oncology, 24(3), 251-254. https://doi.org/10.3747/co.24.3588

Article Metrics

Back to TopTop